Page contentsPage contents Key facts Decision Related content Key facts Active substance pozelimab Therapeutic area Nervous system disorders Decision number EMA/PE/0000257243 PIP number EMA/PE/0000257243 Pharmaceutical form(s) Solution for injection Condition(s) / indication(s) Treatment of myasthenia gravis Route(s) of administration Subcutaneous use Contact for public enquiries Regeneron Ireland DAC E-mail: clinicaltrials@regeneron.com Decision type PM: decision on the application for modification of an agreed PIP Decision date 04/08/2025 Compliance check done No Decision EMA/PE/0000257243 : EMA decision of 4 August 2025 on the acceptance of a modification of an agreed paediatric investigation plan for pozelimabAdopted Reference Number: EMADOC-1700519818-2320688 English (EN) (262.09 KB - PDF)First published: 06/11/2025 View Related content Pozelimab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision English (EN) (43.75 KB - PDF)First published: 23/02/2026 View Share this page